IL300115A - Dosage and Administration of ANTI-C5 Antibodies for Hematopoietic Stem Cell Transplantation Treatment (HSCT-TMA) - Google Patents

Dosage and Administration of ANTI-C5 Antibodies for Hematopoietic Stem Cell Transplantation Treatment (HSCT-TMA)

Info

Publication number
IL300115A
IL300115A IL300115A IL30011523A IL300115A IL 300115 A IL300115 A IL 300115A IL 300115 A IL300115 A IL 300115A IL 30011523 A IL30011523 A IL 30011523A IL 300115 A IL300115 A IL 300115A
Authority
IL
Israel
Prior art keywords
hsct
tma
antibodies
dosage
administration
Prior art date
Application number
IL300115A
Other languages
English (en)
Hebrew (he)
Inventor
Stephan Ortiz
Jonathan Monteleone
Original Assignee
Alexion Pharma Inc
Stephan Ortiz
Jonathan Monteleone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc, Stephan Ortiz, Jonathan Monteleone filed Critical Alexion Pharma Inc
Publication of IL300115A publication Critical patent/IL300115A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL300115A 2020-08-13 2021-08-12 Dosage and Administration of ANTI-C5 Antibodies for Hematopoietic Stem Cell Transplantation Treatment (HSCT-TMA) IL300115A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063065107P 2020-08-13 2020-08-13
PCT/US2021/045823 WO2022036151A1 (en) 2020-08-13 2021-08-12 Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)

Publications (1)

Publication Number Publication Date
IL300115A true IL300115A (en) 2023-03-01

Family

ID=77655658

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300115A IL300115A (en) 2020-08-13 2021-08-12 Dosage and Administration of ANTI-C5 Antibodies for Hematopoietic Stem Cell Transplantation Treatment (HSCT-TMA)

Country Status (10)

Country Link
US (1) US20240209071A1 (cg-RX-API-DMAC7.html)
EP (1) EP4196161A1 (cg-RX-API-DMAC7.html)
JP (2) JP7821160B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230047179A (cg-RX-API-DMAC7.html)
CN (1) CN116249550A (cg-RX-API-DMAC7.html)
AU (2) AU2021326526B2 (cg-RX-API-DMAC7.html)
CA (1) CA3173007A1 (cg-RX-API-DMAC7.html)
IL (1) IL300115A (cg-RX-API-DMAC7.html)
MX (1) MX2023001702A (cg-RX-API-DMAC7.html)
WO (1) WO2022036151A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202426048A (zh) 2022-09-06 2024-07-01 美商阿雷希昂製藥公司 用於治療造血幹細胞移植相關血栓性(hsct-tma)的抗c5抗體的補充劑量和投與
CA3266977A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. DIAGNOSTIC AND PROGNOSIS BIOMARKER PROFILES IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
ES2796078T3 (es) * 2013-09-16 2020-11-25 Childrens Hospital Med Ct Composiciones y métodos para el tratamiento de la microangiopatía trombótica asociada al hsct
NZ711451A (en) * 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
CA3024618A1 (en) * 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
JP7518764B2 (ja) * 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ, インコーポレイテッド 発作性夜間ヘモグロビン尿症(PNH)および非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量および投与
EP3802603A1 (en) * 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
US20230416344A1 (en) * 2020-04-16 2023-12-28 Alexion Pharmaceuticals, Inc. Methods for treating a complement mediated disorder caused by viruses

Also Published As

Publication number Publication date
JP7821160B2 (ja) 2026-02-26
CA3173007A1 (en) 2022-02-17
CN116249550A (zh) 2023-06-09
EP4196161A1 (en) 2023-06-21
JP2023539047A (ja) 2023-09-13
KR20230047179A (ko) 2023-04-06
AU2021326526A1 (en) 2023-03-02
WO2022036151A1 (en) 2022-02-17
MX2023001702A (es) 2023-03-09
JP2026026191A (ja) 2026-02-16
US20240209071A1 (en) 2024-06-27
AU2026201836A1 (en) 2026-05-21
AU2021326526B2 (en) 2025-12-11

Similar Documents

Publication Publication Date Title
IL277025A (en) Methods for improving the differentiation of stem cells into beta cells
IL289011A (en) Use of chimeric antigen receptor t cells and nk cell inhibitors to treat cancer
EA202190162A2 (ru) Способы лечения заболеваний, при которых активность il-13 оказывает негативное влияние, с применением антител против il-13
CR20210088A (es) Composiciones de anticuerpos fcrn y métodos de uso de estos
NZ731735A (en) Anti-pd-1 antibodies and methods of use thereof
SG10201807042YA (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
MX2019000704A (es) Celulas madre mesenquimales primarias inmunoprotectoras y metodos.
SI4121007T1 (sl) Formulacije protiteles proti amiloidnemu beta peptidnemu protofibrilu z visoko koncentracijo in načini njihove uporabe
IL316368A (en) Anti-TL1A antibodies and methods of using them
SG11202010150PA (en) Monoclonal antibody of nerve growth factor and encoding gene and use thereof
IL319413A (en) Adjunctive dosing and administration of anti-C5 antibodies for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA).
IL319674A (en) Human anti-IL-1R3 antibody and methods of use
HK40088954A (en) Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
PL4031569T3 (pl) Przeciwciała przeciwko czynnikowi wzrostu komórek macierzystych i sposoby ich zastosowania
IL288496A (en) A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-il23 antibody
IL315845A (en) Anti-dectin-1 antibodies and methods of using them
IL314656A (en) A component for a transfer system and a method and device for producing a component for a transfer system
Studentsov et al. Adaptogens and related groups of drugs-50 years of searching
MX2023001702A (es) Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la microangiopatia trombotica asociada al trasplante de celulas madre hematopoyeticas (hsct-tma).
IL242791B (en) Antibodies against the toxin ricin
IL319208A (en) Treating asthma with anti-interleukin-33 antibody
IL325425A (en) Dosage and treatment of vaccine-mediated diseases Biomarkers associated with vaccine-mediated diseases
IL318694A (en) Antibodies against CCR8 and methods of using them
BR112022025020A2 (pt) Dosagem de anticorpos neutralizantes de poliomavírus
IL317690A (en) Anti-GPNMB antibodies and methods of using them